Cybin D/B/A Helus Pharma
HELPHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Cybin D/B/A Helus Pharma (HELP) is listed under Biotechnology. With a market capitalization of $905.2M, it sits in small-cap territory. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system.
Market Cap
$905.2M
Beta
0.63
P/E (TTM)
—
P/E (Fwd)
-6.73
EPS (TTM)
$-4.06
EPS (Fwd)
$-1.84
ROE
-86.9%
ROA
-44.4%
Cash
$206,357
Total Debt
$0
Free CF
-$82.4M
52W Change
94.6%
Annual Financials
Cash vs Debt
Where HELP stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, HELP finished 76.56% above its 150-day moving average ($6.57) and 74.17% above its 200-day moving average ($6.66). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HELP overbought or oversold?
At the September 2, 2026 close, HELP's RSI(14) was 51.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Cybin D/B/A Helus Pharma reports $206K in cash and $0 in total debt. The company is burning cash, with free cash flow at -$82.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -86.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
HELP's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing HELP.